Tsushima Shingo, Shibata Tsuyoshi, Iba Yutaka, Sakurada Taku, Muraki Satoshi, Maeda Toshiyuki, Nakajima Tomohiro, Nakazawa Junji, Miura Shuhei, Arihara Ayaka, Nakanishi Keitaro, Mizuno Takakimi, Mukawa Kei, Kawaharada Nobuyoshi
Department of Cardiovascular Surgery, Sapporo Medical University, Sapporo, Japan.
Department of Cardiovascular Surgery, Sapporo Central Hospital, Sapporo, Japan.
J Endovasc Ther. 2024 Dec 18:15266028241305960. doi: 10.1177/15266028241305960.
Previous clinical studies have reported on the short- and mid-term prognoses of thoracic endovascular aortic repair (TEVAR) using the GORE thoracic aortic graft (TAG) or conformable GORE TAG. We evaluated the long-term prognoses of patients who underwent TEVAR using the GORE TAG or conformable GORE TAG in a real-world setting.
This retrospective observational study analyzed the data of all consecutive patients aged 20 years or older who underwent TEVAR using either the GORE TAG or the conformable GORE TAG at a single center. The surgical criteria did not deviate from global standards. In principle, TEVAR was performed with the TAG or conformable thoracic aortic graft (CTAG) according to the manufacturer's instructions. The primary outcomes of this study were the 10-year overall survival rate and the rate of freedom from aorta-related deaths at 10 years.
Between January 2011 and December 2021, 331 patients underwent TEVAR, of whom 175 consecutive patients treated with TEVAR using either the GORE TAG or the conformable GORE TAG were enrolled. The mean age of the patients was 72.1 ± 9.3 years. In addition, the aneurysm and chronic dissection were 61.7% and 38.3%, respectively. Of all patients, 157 had a proximal landing zone ≥3, and 18 had a zone <3. The mean follow-up time was 46.5 ± 33.1 months. The 30-day mortality rate was 2.86%. The 3-, 5-, 7-, and 10-year overall survival rates were 76.9 ± 3.4%, 63.4 ± 4.1%, 55.9 ± 4.9%, and 42.4 ± 8.4%, respectively. The rate of freedom from aorta-related deaths at 3, 5, 7, and 9 years was 97.4 ± 1.3%, 95.0 ± 2.1%, 95.0 ± 2.1%, and 95.0 ± 2.1%, respectively. Late complications occurred in 23 (13.1%) patients. Endovascular re-intervention was performed because of endoleak, false lumen enlargement, or stent graft-induced new entry tear in 14 patients. Three patients required open conversion, and 6 were observed without re-intervention.
Thoracic endovascular aortic repair using the GORE TAG or conformable GORE TAG is a safe and effective procedure for the treatment of thoracic aortic aneurysms and aortic dissection.
Thoracic endovascular aortic repair using the GORE thoracic aortic graft (TAG) or conformable GORE TAG is a safe and effective procedure for the treatment of thoracic aortic aneurysms and aortic dissection. The 30-day mortality rate was 2.86%. During 10 years of follow-up, the overall survival rate was low; however, the risk of aorta-related deaths was also low. No significant differences in freedom from late complications and re-intervention are seen between the TAG and conformable thoracic aortic graft (CTAG) groups. Further investigations into the treatment of late complications are required.
既往临床研究报道了使用GORE胸主动脉移植物(TAG)或顺应性GORE TAG进行胸主动脉腔内修复术(TEVAR)的短期和中期预后。我们评估了在现实世界中使用GORE TAG或顺应性GORE TAG进行TEVAR的患者的长期预后。
这项回顾性观察研究分析了在单一中心接受使用GORE TAG或顺应性GORE TAG进行TEVAR的所有连续20岁及以上患者的数据。手术标准未偏离全球标准。原则上,TEVAR根据制造商的说明使用TAG或顺应性胸主动脉移植物(CTAG)进行。本研究的主要结局是10年总生存率和10年无主动脉相关死亡发生率。
2011年1月至2021年12月期间,331例患者接受了TEVAR,其中175例连续接受使用GORE TAG或顺应性GORE TAG进行TEVAR治疗的患者被纳入研究。患者的平均年龄为72.1±9.3岁。此外,动脉瘤和慢性夹层分别占61.7%和38.3%。所有患者中,157例近端锚定区≥ 3,18例<3。平均随访时间为46.5±33.1个月。30天死亡率为2.86%。3年、5年、7年和10年总生存率分别为76.9±3.4%、63.4±4.1% 、55.9±4.9%和42.4±8.4%。3年、5年、7年和9年无主动脉相关死亡发生率分别为97.4±1.3%、95.0±2.1%、95. 0±2.1%和95.0±2.1%。23例(13.1%)患者发生晚期并发症。因内漏、假腔扩大或支架移植物引起的新破口撕裂,14例患者接受了血管腔内再次干预。3例患者需要转为开放手术,6例患者未进行再次干预而接受观察。
使用GORE TAG或顺应性GORE TAG进行胸主动脉腔内修复术是治疗胸主动脉瘤和主动脉夹层的一种安全有效的方法。
使用GORE胸主动脉移植物(TAG)或顺应性GORE TAG进行胸主动脉腔内修复术是治疗胸主动脉瘤和主动脉夹层的一种安全有效的方法。30天死亡率为2.86%。在10年随访期间,总生存率较低;然而,主动脉相关死亡风险也较低。TAG组和顺应性胸主动脉移植物(CTAG)组在晚期并发症和再次干预方面无显著差异。需要对晚期并发症的治疗进行进一步研究。